New weight loss pill ZT006 enters first human tests
NCT ID NCT07307638
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested ZT006, an experimental daily pill for weight loss, in 94 healthy, overweight, and obese adults. The study checked safety, how the body processes the drug, and the effect of food on absorption. Participants received single or multiple doses, with some also testing the drug after a high-fat meal. The goal is to see if ZT006 is safe enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZT006 (an oral GLP-1 drug)
What this could lead to
If successful, this could lead to a new daily pill for weight management, offering an alternative to injectable GLP-1 drugs.
What could go wrong
This is a very early Phase 1 trial with only 94 healthy participants, focused on safety and dosing. It is not yet tested for long-term weight loss or in people with obesity-related health conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230601, China